Is RAPP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RAPP. It does not provide personalized investment advice.

RAPP (Rapport Therapeutics, Inc. Common Stock) Stock Analysis - Financials

Rapport Therapeutics, Inc. Common Stock (RAPP) is a publicly traded Healthcare sector company. As of July 16, 2026, RAPP trades at $39.95 with a market cap of $1.98B and a P/E ratio of -15.49. RAPP moved -3.76% today. Year to date, RAPP is +31.61%; over the trailing twelve months it is +177.68%. Its 52-week range spans $6.43 to $43.76. Analyst consensus is strong buy with an average price target of $53.71. Rallies surfaces RAPP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are RAPP's key financials?

RAPP financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RAPP recently traded at $39.95. Market cap is $1.98B. P/E ratio is -15.49. Revenue is $20.00M.

RAPP Key Metrics

Key financial metrics for RAPP
Metric	Value
Price	$39.95
Market Cap	$1.98B
P/E Ratio	-15.49
EPS	$-2.59
Dividend Yield	0.00%
52-Week High	$43.76
52-Week Low	$6.43
Volume	201.93K
Avg Volume	0
Revenue (TTM)	$20.00M
Net Income	$-107.28M
Gross Margin	0.00%

RAPP Analyst Consensus

8 analysts cover RAPP: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.71.

Common questions about RAPP

What are RAPP's key financials?: RAPP financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RAPP recently traded at $39.95. Market cap is $1.98B. P/E ratio is -15.49. Revenue is $20.00M.
Is RAPP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RAPP. It does not provide personalized investment advice.